Healthcare M&A: where the next advisory mandates are forming

The deals are public. The mandates aren't — yet. Across European and Gulf health systems, here's how to read the signal weeks before the RFP exists.

Every advisory mandate has a paper trail that predates it. A deal closes; an operating model has to be rebuilt; a sponsor needs a hundred-day plan — and somewhere in that gap, weeks before anyone issues an RFP, the mandate already exists in all but name. Healthcare is the cleanest example in the market right now, because the deal flow is unusually legible and the value-creation work is unusually heavy.

And the flow is accelerating. Tracked across our EMEA Health & Life Sciences universe, disclosed deal volume has more than tripled since November — a run that historically front-runs a wave of integration and transformation mandates by one to two quarters.

Look at the last month of European deals and the pattern almost announces itself: a Triton-backed Nordic roll-up, an Iberian buy-and-build, a co-control take-private in the UK — each one opening the same operating-model window the moment it closes.

It's not the headline size — it's the structure

Most of this flow is mid-market, and that matters. The bulk of disclosed value sits in the €50m–€1bn bands — exactly the range where buyers lack in-house transformation capacity and reach for external advisors. The mega-deals make the headlines; the mid-market makes the mandates.

A single deal is an event. A sequence of deals in one sector, all opening the same operating-model window, is a pipeline.

Selected transactions — the last 30 days

Every one of these opens a different door: post-acquisition integration, a cross-border market entry, pre-exit preparation. The pattern tag is the tell — it's the shape of the mandate forming behind the announcement.

The Gulf is running a different clock

In the GCC the signal isn't the deal — it's the structural build-out. Vision 2030 and regional diversification are re-platforming health faster than the procurement cycle can keep up. Sovereign capital is deploying directly: ADQ behind PureHealth, Mubadala building M42 with G42, PIF standing up Lifera in biopharma. Providers are consolidating and listing — Fakeeh and Almoosa onto Tadawul, Burjeel on the ADX — each listing dragging a tail of readiness, governance and post-IPO operating mandates behind it.

None of these arrive as an RFP first. They arrive as a hiring move, a regulatory filing, a sovereign press release, a new CFO — signals that compound for weeks before procurement formalises what everyone close to the situation already knows. The firms that win these aren't working harder than everyone else. They're simply earlier.

That's the entire premise of what we do: take the fragmented public signal across thousands of companies and sequence it into a ranked, evidence-backed feed of mandates forming now — so the conversation starts before the RFP, not after.